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Transcriptional states are formed and maintained by the interaction and post-translational
modification (PTM) of several chromatin proteins, such as histones and high mobility group
(HMG) proteins. Among these, HMGA1a, a small heterochromatin-associated nuclear protein
has been shown to be post-translationally modified, and some of these PTMs have been linked
to apoptosis and cancer. In cancerous cells, HMGA1a PTMs differ between metastatic and
nonmetastatic cells, suggesting the existence of an HMGA1a PTM code analogous to the
“histone code.” In this study, we expand on current knowledge by comprehensively
characterizing PTMs on HMGA1a purified from human cells using both nanoflow liquid
chromatography collision activated dissociation mediated Bottom Up and electron-transfer
dissociation facilitated middle and Top Down mass spectrometry (MS). We find HMGA1a to
be pervasively modified with many types of modifications such as methylation, acetylation,
and phosphorylation, including finding novel sites. While Bottom Up MS identified lower
level modification sites, Top and Middle Down MS were utilized to identify the most
commonly occurring combinatorially modified forms. Remarkably, although we identify
several individual modification sites through our Bottom Up and Middle Down MS analyses,
we find relatively few combinatorially modified forms dominate the population through Top
Down proteomics. The main combinatorial PTMs we find through the Top Down approach are
N-terminal acetylation, Arg25 methylation along with phosphorylation of the three most
C-terminal serine residues in primarily a diphosphorylated form. This report presents one of
the most detailed analyses of HMGA1a to date and illustrates the strength of using a combined
MS effort. (J Am Soc Mass Spectrom 2010, 21, 960–970) © 2010 Published by Elsevier Inc. on
behalf of American Society for Mass SpectrometryAlthough the human genome has been sequencedfor nearly a decade, the understanding of theepigenome, the set of factors superimposed
over the DNA sequence that determine gene expression
across cell types and developmental stages, remains
incomplete [1]. A major locus for epigenetic regulation
is the nucleosome, the basic unit of chromatin which
consists of 146bp of DNA wrapped around an octamer
of histone proteins [2]. Histones are subject to various
post-translational modifications (PTMs), including meth-
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tion, which serve as markers for transcriptionally active
or silent chromatin among other roles [3]. Proteins that
recognize specific histone modifications bind histones to
effect changes in chromatin structure. Heterochromatin
Protein 1 (HP1), for example, binds selectively to trimethy-
lated H3 lysine 9 and results in the formation of transcrip-
tionally inert heterochromatin [4, 5].
For many chromatin-associated proteins, however,
the mechanisms and consequences of interactions with
nucleosomes are less clear. The high mobility group
(HMG) proteins are well-characterized nuclear proteins
termed “architectural transcription factors” because
they associate with nucleosomes to modify chromatin
structure and modulate specific gene expression [6].
HMG proteins are divided into three families based
on their binding domains: HMGA, which contain AT-
hooks and bind preferentially to theminor groove of DNA
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domains that bind to the minor groove of DNA with no
known specificity; and HMGN, which bind directly
to nucleosomes. Mammalian HMGA proteins include
HMGA1a, HMGA1b, and HMGA2 [7]. HMGA1a and
HMGA1b are simply transcript variants, where HMGA1a is
the full length isoform. Among these, the role of
HMGA1a in chromatin remodeling is especially intrigu-
ing because this protein is an oncoprotein that is only
expressed at high levels in cancer cells [8–10] and
during embryonic development [11, 12]. HMGA1a is a
highly mobile protein that is found throughout the
nucleus, however, it has been shown to be enriched in
heterochromatin [13, 14]. The three AT-hook binding
motifs of HMGA1a enable it to bind to the minor
groove of DNA and alter chromatin structure [15, 16].
HMGA1a modifies chromatin structure by altering the
rotational setting of DNA bound to nucleosomes [15].
Unlike most transcription factors, HMGA1a possesses
the remarkable ability to bind DNA recognition sites
that are wrapped around nucleosomes and uncover
promoters for transcription factor binding [17]. Like
histones, HMGA1a is subject to extensive PTMs, includ-
ing phosphorylation, acetylation, and methylation [7].
Phosphorylation of serine and threonine residues are
the most prevalent PTMs observed [18, 19]. Research
suggests that PTMs on HMGA1a have functional impli-
cations on this protein’s ability to remodel chromatin.
Phosphorylation reduces HMGA1a DNA binding affin-
ity, [20] and specific phosphorylation patterns correlate
to higher residence in heterochromatin [21]. HMGA1a
has also been found to be modified in human cancer cell
lines [22, 23].
Recently, mass spectrometry (MS) based proteomic
investigations have advanced our knowledge of HMGA
PTMs. Sgarra et al. used MS coupled to reverse phase
HPLC and found that increased arginine methylation of
HMGA1a is associated with apoptosis and possibly
with heterochromatin formation [24]. Studies using
matrix-assisted laser desorption ionization (MALDI)
with time-of-flight (TOF) MS alone or in combination
with electrospray ionization (ESI) tandem mass spec-
trometry (MS/MS) identified differences in HMGA1a
PTMs patterns in metastatic and non-metastatic cancer
cell lines, suggesting the existence of a PTM code
analogous to the histone code [23, 25]. Zou et al. utilized
MS/MS to characterize sites of phosphorylation on
HMGA1a from human prostate cancer cells; in addition
to three distinct phosphorylation sites, Arg25 was
found to be mono- and di-methylated [26]. Subsequent
LC-MS investigations by this same group identified Arg
57 and Arg 59 as in vivo methylation sites as well [27].
MALDI-MS/MS together with LC-ESI-MS/MS was
used to examine HMGA1a PTMs in PC-3 human pros-
tate cancer cells that were either treated or not treated
with a histone deacetylase inhibitor [28]. This study
found Ser 35, Thr52, Thr77, Ser98, Ser101, and Ser102 to
be phosphorylated while Arg25 was found to be meth-
ylated. Lys14 was found to be acetylated in the cells thatwere not treated with butyrate [28]. The same instru-
mentation was used in a different investigation to find
novel HMGA1a PTMs including Lys30me1, Lys54me1,
Ser43phos, and Ser48phos, in addition to previously
reported marks [29]. LC-MS/MS was also used to
quantitate HMGA1a lysine acetylation [30]. Zou et al.
found arginine methylation sites by the protein arginine
methyltransferase family through MALDI-MS [31].
Lastly, LC-MS/MS was used to investigate HMGA
protein expression and macroscopic PTM differences
across different cell lines [32].
Nevertheless, while a significant number of studies
have detailed a wide array of HMGA1a PTMs, a com-
prehensive investigation into potential combinatorial
PTM patterns on HMGA has not been reported. In this
study, we expand on current knowledge by comprehen-
sively characterizing PTMs on HMGA1a purified from
human HeLa S3 cells using Top and Middle Down as
well as Bottom Up proteomic approaches. The Bottom
Up approach enzymatically digests HMGA1a into short
peptides before MS analysis and provided a sensitive
platform to detect modifications of sub-stoichiometric
abundance [33], while the Top and Middle Down
approaches involve the analysis of large polypeptides
and intact proteins, and are ideal for probing long-
range PTM combinations [34, 35]. Using Bottom UpMS,
we find HMGA1a to be extensively modified with all
degrees of lysine methylation, lysine acetylation, argi-
nine methylation and phosphorylation of threonine and
serine residues at varying abundance levels including
detecting some novel HMGA1a modifications. Middle
and Top Down analyses revealed the identity of the
most abundant combinations of modifications present
on HMGA1a. The most abundant isoforms present in
HeLa cells were determined to be N-terminally acety-
lated and di-phosphorylated at Ser98, Ser101, or Ser102.
Only the Ser101phSer102ph form was detected by Bot-
tom Up mass spectrometry, suggesting this may be the
prevalent form. Additionally the overwhelmingly most
abundant site of methylation was found to be Arg25.
Un-, mono- and tri- phosphorylated forms were also
observed always in combination with N-terminal acet-
ylation and variably with methylation. The amount of
methylation observed on each of these forms appeared
independent of the other modifications present. Our
multifaceted approach proved to produce very comple-
mentary data on this highly modified chromatin pro-
teins and underscores the need for multiple approaches
in characterization of protein modifications.
Experimental
Cell Culture and Purification of HMGA1a
HeLa S3 cells were grown and harvested as described
by Thomas et al. [36], while nuclei were isolated as
described by Garcia et al. [37], and HMG proteins were
acid extracted from HeLa cells as described by Reeves
[38]. Briefly, HMG proteins were acid extracted from
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trichloroacetic acid (TCA) followed by washes with
acetone containing 0.1% HCl and then pure acetone.
The resulting pellets were redissolved in 1 mL deion-
ized water and fractionated on a C18 column (4.6
mm i.d.  250 mm; Vydac, Hesperia, CA, USA) using
an Beckman Coulter System Gold HPLC (Fullerton,
CA, USA) with a linear gradient of 1% B per min (A 
5% MeCN in 0.2% TFA, B  90% acetonitrile in
0.188% TFA). Fractions containing HMGA1a proteins
were pooled and dried to completion in a SpeedVac
concentrator.
Sample Preparation for Bottom Up and Middle
Down Mass Spectrometry
HMGA1a was digested into short peptides suitable for
Bottom Up mass spectrometry by digestion with tryp-
sin. Briefly, purified HMGA1 was resuspended in 100
mM ammonium bicarbonate (pH  8.0) and digested
for 6 h at 37 °C using trypsin (Promega, Madison, WI,
USA) at a protein:enzyme ratio of 20:1. For Middle
Down MS, a limited trypsin digestion was used with
the reaction being quenched after 2 h. Alternatively,
HMGA1a was derivatized by treatment with propionyl
anhydride reagent essentially as described before [39,
40]. Briefly, this reagent was created by mixing 75 L of
MeOH with 25 L of propionic anhydride (Sigma
Aldrich, St. Louis, MO, USA). Equal volumes of reagent
and HMGA1a protein were mixed and allowed to react
at 37 °C for 15 min. Propionylated HMGA1a was then
digested with trypsin after dilution of the sample with
100 mM ammonium bicarbonate buffer solution. The
reaction was quenched by the addition of concentrated
acetic acid and freezing (80 °C). Following removal of
reaction remnants and by-products through vacuum
centrifugation, a second round of propionylation was
then performed to propionylate the newly created pep-
tide N-termini.
NanoLC-MS/MS for Bottom Up and Middle
Down Mass Spectrometry
A small aliquot of the resulting peptides from both of
the peptide digests were desalted using homemade
stop and go extraction (STAGE) tips as previously
described [41]. Briefly, peptides were twice eluted from
STAGE Tips using 20 L of 75% acetonitrile, 5% acetic
acid. The resulting volume was reduced to5 L in the
SpeedVac. Peptides were acidified with 1 L of 0.1%
acetic acid. All mass spectrometry experiments were
performed in the following manner. Peptide samples (2
L) were loaded by an Eksigent AS-2 autosampler
(Eksigent Technologies Inc., Dublin, CA, USA) onto a
fused silica micropapillary (75 m) column constructed
with an integrated ESI tip and packed in-house with 5
um C18 YMC ODS-A resin. Peptides were HPLC sepa-
rated with an Agilent 1200 series binary pump with anin-line flow splitter across a 110 min linear gradient
ranging from 2 to 35% Buffer B (Buffer A  0.1 M acetic
acid, Buffer B  70% acetonitrile in 0.1 M acetic acid)
with a constant flow of 100–200 nL/min. Alterna-
tively, a 150 min linear gradient from 2% to 35% buffer
B was used if higher chromatographic resolution was
desired. The HPLC system was coupled to an LTQ-
Orbitrap mass spectrometer (ThermoFisher Scientific,
San Jose, CA, USA) operated with a spray voltage set to
2.7 kV. Survey full scan MS spectra (m/z 290–1650) were
acquired in the Orbitrap with a resolution of 30,000 at
m/z 400 after accumulation of 500,000 ions. For colli-
sionally activated dissociation (CAD), the 10 most in-
tense ions from the preview scan from the Orbitrap
were sequenced (normalized collision energy 35%) in
the LTQ after accumulation of 10,000 ions concur-
rently to full scan acquisition in the Orbitrap. Maximum
filling time was 500 ms for the full scans. Precursor ion
charge state screening was enabled and all unassigned
charge states as well as singly charged species were
rejected. The dynamic exclusion list was restricted to a
maximum of 500 entries with a maximum retention
period of 120 s and a relative mass window of 1 Da.
Data were collected in centroid mode.
Top Down Mass Spectrometry of HMGA1a
HPLC purified HMGA1A was infused at 0.5 L/min
via nanospray ionization into an LTQ-Orbitrap mass
spectrometer equipped with electron-transfer dissocia-
tion (ETD). The analyte automatic gain control (AGC)
was set to 7E5 for full MS and 2E5 for tandem MS
analysis with an isolation width of 3 m/z. The ETD
reagent anion AGCwas set to 1E6 and a reaction time of
15 ms was used. A microscan count of 10 was used for
both full MS and tandem MS and 10 min of data
were acquired and averaged for each spectrum. All
data were acquired in the Orbitrap analyzer set at
100,000 resolution.
Data Analysis
For HMGA1a PTM detection, CAD mass spectra were
searched using the SEQUEST algorithm within the
Bioworks Browser (version 3.3.1 SP1; Thermo Fisher
Scientific Inc., San Jose, Ca, USA) against a human
protein database derived from sequences obtained from
the National Center for Biotechnology Information
(NCBI) database (August 2008). Trypsin and keratin con-
taminant proteins were also included in this database.
Enzyme specificity was set to trypsin, fully enzymatic,
allowing for up to five missed cleavage sites (since endog-
enous and chemical modification of lysine residues hin-
ders enzymatic digestion and a 2 h limited trypsin digest
was performed). Propionylation (56.026Da) on the
N-terminus of the proteins and peptides was set as a fixed
modification. For HMGA1a PTM searches, Lys propiony-
lation, Lys acetylation (42.010Da), monomethyl on Lys
residues (70.042Da), and Arg residues (14.010 Da), dim-
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tion (42.046Da), and Ser and Thr phosphorylation
(79.966Da) were selected as variable modifications.
HMGA1a monomethylation was searched as the sum of
the masses for propionylation and methylation because
monomethylated residues can still be propionylated.
Mass tolerances were set to 0.05 m/z for parent ions and
fragment ion tolerance was set to 0.5 m/z. Resulting
peptide lists were filtered using standard criteria (Pro-
tein Probability  1E-5, Xcorr  2.0, 2.5, and 3.0 were
used for peptide charges of 2, 3, and 4 respectively) as
Figure 1. Differentiating post-translational mo
CAD tandem spectrum of an [M 2H]2 ion at 9
digest showing the peptide with the sequence pr-
MS/MS spectrum and fragment map for a doubly
(a) Nevertheless, the b and y type fragments allow
having the sequences of the HMGA1a peptide pr
pr-GRPK prGSK prme1NK prGAAK prTR (Lys64me1); prpreviously used [42]. The false positive rate was esti-
mated to be the 1% level for protein ID by searching a
reverse database. All spectra from modified peptides
were also manually inspected.
For analysis of Top Down mass spectrometry data,
both computational and manual data interpretation was
used to interpret the ETD tandemMS data. Ion peaks in
the tandem MS were first identified and converted into
their monoisotopic values using a THRASH algorithm
and isotopic fitting [43]. Using a set of post-translational
modifications that have been reported or discovered by
tion isomers by tandem mass spectrometry. (a)
5 m/z at from the propionylated HMGA1a trypsin
prGSKprNKprGAAKme1TR (Lys70me1). (b) CAD
ged ion at the same 925.535 m/z as the species in
the identification of two different distinct species
K GSK NK GAAK TR (Lys61me1) anddifica
25.53
GRPK
char
for
-GRP prme1 pr pr pr
 propionyl amide, ac  acetyl.
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fragment masses was generated by independently start-
ing from the N-terminus for the c-ion series and the
C-terminus for the z·-ion series and then matching these
theoretical fragments to the monoisotopic peak list. A
modified version of the previously described integer
linear optimization model [44] was utilized to discover
modified forms that are (1) consistent with the parent
mass within 28 Da and (2) maximize the supporting
evidence found in the in silico list. The supporting ions
corresponding to the modified forms reported for each
spectrum were manually validated before concluding
their presence or absence. Manual spectral interpreta-
tion was also used to thoroughly reveal additional
supporting ions as needed.
Results and Discussion
In this article, we describe the intensive characterization
of HMGA1a PTMs using a combination of Bottom Up
together with Middle and Top Down proteomic ap-
proaches. HMGA1a was purified from asynchronously
grown HeLa cells using standard perchloric acid
extraction followed by reverse phase HPLC separa-
tion essentially as previously described [38]. Our over-
all goal was to identify potential combinatorial modifi-
cation patterns on HMGA1a. However, before we
attempted to resolve any combinatorial PTM patterns
by MS, we decided to create a comprehensive PTM
inventory of HMGA1a. To accomplish this, we turned to
Bottom Up proteomic analyses performed via nanoflow
Table 1. List of selected modified HMGA1a peptides detected thr
Peptide Calc. mas
ac-SESSSKprSSQPLASKprQEKprDGTEKprR 920.789
ac-SESSSKprSSQPLASKacQEKprDGTEKprR 916.117
ac-SESSSKprme1SSQPLASKprQEKprDGTEKprR/
ac-SESSSKprSSQPLASKprQEKprDGTEKprme1R
925.461
pr-GRPKprGSKprNKprGAAKprTR 918.526
pr-GRPKprGSKprNKprGAAKprme1TR/
pr-GRPKprGSKprme1NKprGAAKprTR/
pr-GRPKprme1GSKprNKprGAAKprTR
925.534
pr-GRPKprGSKacNKprGAAKprTR/
pr-GRPKprGSKprNKacGAAKprTR
911.519
pr-KprTTTTPGRKprPR 705.907
pr-Kprme1TTTTPGRKprPR 712.915
pr-KacTTTTPGRKprPR 698.899
pr-KprTTTTphosPGRKprPR 745.890
KLEKEEEEGISQESSEEEQ 746.336
KLEKEEEEGISQESphosSphosEEEQ 799.647
KQPPVSPGTALVGSQKEPSEVPTPK 640.352
KQPPVSPGTALVGSphosQKEPSEVPTPK/
KQPPVSphosPGTALVGSQKEPSEVPTPK/
KQPPVSPGTALVGSQKEPSEVPTphosPK/
KQPPVSPGTALVGSQKEPSphosEVPTPK/
KQPPVSPGTphosALVGSQKEPSEVPTPK
660.343
KQPPVSphosPGTALVGSQKEPSEVPTphosPK 680.334
KQPPVSPGTALVGSQKEPSEVPTPK (3 phos)* 700.326ac  acetyl; me1  monomethyl; phos  phosphoryl; pr  propionyl amide
*Could not localize modification sites.LC-MS/MS on a high-resolution Orbitrap mass spec-
trometer; in our laboratory, we find this approach
provides the most sensitive measurement of protein
PTMs. First, HMGA1a was derivatized by treatment
with propionic anhydride reagent followed by trypsin
digestion, a procedure we have previously optimized
for histone protein PTM analysis [39, 40]. Propionyla-
tion blocks endogenously unmodified and monomethy-
lated lysine residues, and thus this protocol generates
predictable Arg-C like peptides that are of near opti-
mum length for interrogation by CAD based tandem
mass spectrometry. Through this approach, we detected
many well known HMGA1a modifications. Supplemen-
tal Figure 1, (which can be found in the electronic
version of this article) displays an MS/MS spectrum
obtained of the [M  3H]3 ion at 916.118 m/z from the
1-23 peptide of propionylated HMGA1a, and analysis
of the fragment ions indicated that both the N-terminus
and Lys14 were acetylated. This lysine residue has been
previously shown to be acetylated by acetyltransferases
PCAF (p300/CBP-associated factor) and p300 [28, 30]. It is
interesting to note that in our experiments, we never
detected non-N-terminally acetylated HMGA1a protein.
These experiments also revealed the presence of
several novel modification sites as well. For instance,
we observed monomethylation of HMGA1a on the
peptide GRPKGSKNKGAAKTR, and inspection of differ-
ent MS/MS spectra showed evidence for monom-
ethylation of three distinct internal lysines on that
peptide. Figure 1a displays an MS/MS spectrum of
the [M  2H]2 ion confirming the sequence pr-
nanoLC-MS/MS approaches (bottom up and middle down MS)
Obs. mass Peptide charge Relative abundance
920.793 3 93.5%
916.115 3 1.3%
925.469 3 5.2%
918.525 2 99.5%
925.531 2 0.3%
911.515 2 0.2%
705.904 2 97.8%
712.912 2 0.4%
698.897 2 1.5%
745.887 2 0.3%
746.338 3 3.7%
799.647 3 96.3%
640.354 4 51.9%
660.344 4 38.0%
680.335 4 10.0%
700.326 4 0.1%ough
s(chemical derivatization).
displa
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tionally, we observed other tandem mass spectra of the
GRPKGSKNKGAAKTR peptide that also contained
monomethyl modification, albeit at different lysine res-
idues. For example, manual inspection of an MS/MS
spectrum (Figure 1b) of the doubly charged ion at
925.535 m/z determined that this spectrum was com-
posed of two positional isomeric species containing
monomethyl either at Lys61 or Lys64. This is clearly
evident as fragment ions separated by 14 Da can be seen
throughout the MS/MS spectrum, such as at 1285 and
1299 m/z (y11 ions), and at 551 and 565 m/z (b4 ions),
providing support for monomethylation at both sites.
Lys64 and Lys70 on HMGA1a have only been previ-
ously reported to be acetylated; [7] thus we find
monomethylation of Lys61, Lys64, and Lys70 to be
novel HMGA1a modifications. Interestingly, we did not
observe higher degrees of methylation at those specific
lysine residues, indicating that if existing, these higher
degrees of methylation are present below our current
detection limit. Modified peptides detected through this
chemical derivatization Bottom Up MS strategy are
listed in Table 1.
While this Bottom Up propionylation procedure
allowed for extensive sequence coverage of the N- and
Figure 2. Middle down MS analysis of HMGA
680.335 m/z from the limited trypsin digest of HM
KQPPVSphosPGTALVGSQKEPSEVPTphosPK,C-termini of HMGA1a, we obtained little sequence cover-age of the middle portion of the protein (residues 25–60)
and, hence, potential PTMs in those regions remained
elusive. We felt that the peptides generated in this region
through the propionylation procedure were possibly too
low a charge state to be ionized efficiently for the large size
of the peptide (propionylation removes charge from lysine
residues producing mostly 2 ions), and detection of
those larger peptides could be actually hindered by this
method. Aiming to access peptides covering this section,
we then performed a partial tryptic digest (2 h) on
HMGA1a with no propionylation derivatization per-
formed either before or after the digest. Such digestion
rendered peptides from the mid-region that were essen-
TD MS/MS spectrum of a triply charged ion at
1a. This peptide was determined to primarily be
ying a combinatorial phosphorylation pattern.
Figure 3. Sequence coverage and post-translational modifica-
tions found on HMGA1a through nanoLC-MS/MS approaches
(Bottom Up andMiddle Down). Sequence coverage is indicated by1a. E
GAunderlined regions.
nt de
966 YOUNG ET AL. J Am Soc Mass Spectrom 2010, 21, 960–970tially of the same size as those produced before, but with
higher charge states (3), thus facilitating a “Middle
Down” like characterization of the mid-portion of the
HMGA1a protein. As Middle DownMSmethods analyze
modifications on large polypeptides; the connectivity be-
tween different modifications can be partially preserved
through this approach as shown on histone proteins [37,
45]. Through this approach, we find that some HMGA1a
post-translational modifications can occur in combi-
nation simultaneously. For example, an ETD tandem
mass spectrum taken of the [M  3H]3 ion at 680.335
m/z was found to have been generated from the
peptide KQPPVSphosPGTALVGSQKEPSEVPTphosPK,
phosphorylated on Ser35 and Thr52 (Figure 2), and
evidence for other minor di-phosphorylated forms
were also present (data not shown). We detected
many distinct phosphorylation sites on the peptide
Figure 4. Full mass spectrum of the 14th charge
in suspension. The modification state of the peaks
2) and Top Down ETD tandemMS sequencing (se
diphosphorylated species. Note also that the relativ
to unmethylated forms is consistent across differe
Table 2. A semiquantitative list of the most abundant modificat
abundant isotopic peaks. In all cases the ppm error (part per mil
approximate percent of that each species represents relative to th
diphosphorylated make up about 75% of the mixture and the rem
Modification state Exp. m/z Exp. Da
ac1ph2 840.0117 11746.0619
me1ac1ph2 841.0122 11760.0689
ac1 828.5878 11586.1273
ac1ph1 834.2993 11666.0883
ac1ph3 845.7232 11826.0233
me1ac1ph3 846.7242 11840.0367
me1ac1 829.5900 11600.1581
me1ac1ph1 835.2995 11680.0911KQPPVSPGTALVGSQKEPSEVPTPK, but unlike the
peptide mentioned above, most of them were only
detected singly and not in combination (Table 1). This
might indicate that the combinational phosphoryla-
tion pattern of HMGA1a at these sites is severely
limited and/or low level, or may only occur in vivo
under some specific cellular conditions.
After Bottom Up and Middle Down characterization,
we find HMGA1a to be pervasively modified with
many types of PTMs. A summary of all modifications
we identify by Bottom Up and Middle Down MS
approaches is presented in Figure 3 and Table 1. In all,
we detect lysine methylation and acetylation as well as
serine and threonine phosphorylation. Formylation has
been recently discovered as an abundant modification
on several chromatin associated proteins including
Lys30 on HMGA1a [46]; unfortunately, we did not find
of HMGA1A derived from HeLa S3 cells grown
beled based on accurate mass analysis (see Table
re 5). Note that the spectrum is dominated by the
owithin a phosphorylation state of themethylated
grees of phosphorylation.
tates of HMGA1A. Both m/z and masses are for the most
in within 2 ppm as expected. In the final column the
. The two most abundant species that are both
ng forms are relatively low level
Theo. Da ppm Error Approx. %
11746.0650 –0.3 51.6
11760.0806 –1.0 23.8
11586.1323 –0.4 6.0
11666.0987 –0.9 5.0
11826.0313 –0.7 4.8
11840.0470 –0.9 3.5
11600.1480 0.9 2.8state
are la
e Figu
e ratiion s
lion)
e sum
aini11680.1143 –2.0 2.5
967J Am Soc Mass Spectrom 2010, 21, 960–970 TOP AND MIDDLE DOWN AND BOTTOM UP MS ANALYSIS OF HMGA1aevidence of formylation in our study. We found novel
modification sites including lysine methylation on Lys6,
Lys22, Lys61, Lys64, Lys70, Lys73, as well as phosphor-
ylation on Thr38 (Figure 3 and Table 1). Nevertheless,
although we detect a large variety and number of
HMGA1a post-translational modifications, we find lit-
tle evidence for simultaneously occurring combinatorial
modifications. This observation prompted us to attempt
to estimate the relative modification level of each mod-
ified peptide by measuring the abundance of the mod-
ified peptide expressed as the ratio of the modified
peptide over the sum of the modified and unmodified
forms of that peptide, as we have previously performed
for histone proteins [40]. The relative abundances of all
the modified peptides are also listed in Table 1. Most
modified peptides are of very low abundance (5%);
this suggests that most modified forms of HMGA1a are
in very few specialized locations in the human genome.
However, not all modifications are of low abundance;
in particular, phosphorylated forms of the C-terminal
serine residues on HMGA1a were found at relatively
high levels compared with most modifications, prompt-
ing speculation that these sites are constitutively phos-
phorylated (Table 1). Previous LC-MS profiling experi-
ments have found various phosphorylation states on
intact HMGA1a; [32] accordingly, our assessment of the
high abundance of C-terminal phosphorylation is in
agreement with this prior report.
Despite the many modification sites observed, we
could not detect a large variety of combinatorial PTM
complexity through Bottom Up and Middle Down
approaches. Thus, we decided to take this kind of
experiment one step further and explore the possibility
of combinatorial PTM codes on HMGA1a through a
Top Down MS proteomic approach. We reason that pos-
sibly the combinatorial modifications may span much
longer regions of the protein than those we produced and
examined using Bottom Up and Middle Down MS; there-
fore, Top Down MS may be the only method suitable to
study HMGA1a combinatorial PTMs. Additionally, we
found that by using both a Bottom Up and Middle Down
approach, we did not detect many peptides with Arg
modifications, although those types of modifications are
some of the most well known and studied HMG PTMs
[24, 26]. A Top DownMS experiment essentially provides
100% sequence coverage (although PTM localization is
more challenging), and would enable the identification of
PTMs missed in our previous MS analysis of HMGA1a
digested samples as well.
HPLC purified HMGA1a extracted from asynchro-
nously grown HeLa cells was dissolved in 50% MeCN/
0.1% formic acid and nanoelectrosprayed into the Or-
bitrap mass spectrometer. In Figure 4, the full MS of the
purified HMGA1a is zoomed in on the 14 charge state
spanning the 825–865 m/z range. Multiple peaks can be
seen corresponding to various combinations of PTMs
over the expected baseline molecular mass of HMGA1a.
Extrapolated masses of the eight more easily detectable
species are presented in Table 2; the high mass accuracyof the instrument allowed for sub-2 ppm determina-
tions of the masses. The mass of the major peak,
840.0117 m/z is consistent with a doubly phosphory-
lated and monoacetylated species as shown in Table 2.
This species makes up 50% of the HMGA1A recov-
ered from normally grown HeLa cells. The second most
abundant species (25% of the total mixture) is the
diphosphorylated, monoacetylated and monomethyl-
ated peak at 841.0122 m/z. Thus the diphosphorylated
forms constitute over 75% of the HMGA1a in normally
grown HeLa S3 cells. Most other peaks are primarily
analogs of these peaks (acetylated and acetylated 
monomethylated) with 0, 1, and 3 phosphorylations.
Interestingly, the ratio between the acetyl and the
acetylated  monomethyl forms remain essentially the
same regardless of the phosphorylation state. This
spectrum shows relatively limited adduct formation,
such as the potassium adducts labeled, which are
typical for intact protein mass spectra. Likely other
forms are present, accounting for the other modifica-
tions observed in the Bottom Up analysis, but are at
fairly low levels and obfuscated by interference with
adducts. Nevertheless, this data is consistent with our
Bottom Up and Middle Down analyses demonstrating
that the combinatorial modifications of HMGA1a are
fairly limited. A few relatively simple combinatorial
forms dominate the population and additional low level
modifications likely combine with these apparently
constitutive modifications but likely not in extensive
combination with each other.
Top Down MS analysis of the major ions observed in
the full MS at 840 and 841 m/z indicate that these two
major forms are both acetylated and diphosphorylated.
From our Bottom Up experiments, we concluded that
HMGA1a was always detected as being N-terminally
acetylated (Supplemental Figure 1). Therefore, we ex-
pected that all these protein forms which contain an
acetyl group were merely N-terminally acetylated. In-
deed, inspection of the c and z type fragment ions from
the ETD-MS/MS spectrum (Figure 5) of the most abun-
dant species at 841 m/z  1.5 m/z with the 14 charge
state showed that the acetyl group was on the N-
terminus. This is also shown in ion map form in Figure
6. The c-ion series locates the acetylation site on the
N-terminus as it starts relatively low at c5ac1
1. This
small protein fragment (SESSS) is only capable of acet-
ylation at the N-terminus. Further examination of the
fragment ions in the spectrum also pointed to the likely
sources of diphosphorylation was through the combi-
nation of two residues at Ser98, Ser101 or Ser102 (z26 ion
at 1600 m/z, Supplemental Figure 2). Unfortunately, our
z ion series does not allow for the precise identification
of the two residues near the carboxy-terminus that are
phosphorylated. HMGA1a ETD spectra usually exhibit
extensive sequence coverage except for the last 24
amino acids near the C-terminus. This section of the
protein (RGRPKKLEKEEEEGISQESSEEEQ) is very rich
in glutamic acid residues making it challenging to main-
tain sufficient positive charge for MS detection especially
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theory could maintain charge, did not reach these depths,
stopping at c73. Our Bottom Up data is in perfect agree-
ment with the Top Down data indicating that the major
sites of phosphorylation are at the C-terminus. The Bot-
tom Up MS experiments only detected positive evidence
for the Ser101phSer102ph diphosphorylated form out
of the three possible combinations (Ser98phSer101ph,
Ser98phSer102ph and Ser101phSer102ph). Although
not quantitative, this appears to indicate that
Ser101phSer102ph is the dominant form. The c-ion
series provides more information to identify the exact
site of methylation on the secondary form. Our ETD-
MS/MS analysis confirmed that the secondary modi-
fied form is monomethylated at Arg25 with supporting
ions (3 c25 ion at about 920 m/z and beyond) shown in
Figure 5. The many ions before c25 show no signs of
methylation and more than 20 ions after and includ-
ing c25 exhibit clear ac1me1 peaks (Supplemental
Figure 2). This is critical information on the primary
site of methylation; this site is conspicuously absent
from the Bottom Up analysis due to the density of
arginine residues in the region. The z-ion series also
extends deep enough to also help confirm the loca-
tion of the methylation of the secondary form (e.g.,
z86me1ph26,6 ion at about 1608 m/z) and even
exhibit apparent z104 and z105 ions that constitute the
entire protein less the first one or two residues on the
N-terminus. Overall, more than 180 peaks were used for
identificationwith an rms error of 1.3ppm, and a fragment
map of the ETD driven Top Down analysis of the two
major forms of HMGA1a en masse is shown in Figure 6.
Multiple alternative hypotheses derived from our compu-
tational methods were also tested by manual validation,
but generally were found to be caused by interferences
from the validated forms, lacking the consistent and
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 5. A Top Down ETD spectrum of the di
m/z  1.5 m/z. The major forms are identified are
near the C-terminus and the less abundant form
Figure 6. ETD based fragment map of the Top Down MS
analysis of HMGA1a obtained from fragmentation produce in
Figure 5. The methylation on Arg25 is variable (there is also an
unmethylated form in the spectrum). The C-terminal phosphory-
lations are at two out of three of the serines indicated. The Bottom
Up data only supports the two phosphorylations being at the two
more C-terminal sites (Ser101phSer102ph).into four unequal sections for clarity. Due to space livoluminous evidence for the top fitting forms. The sup-
port for these hypothetical forms was generally relatively
weak; we believe such support is due exclusively to the
density of peaks in the spectrum and the wide range of
possible modifications considered in combination. The
algorithm did however correctly identify the top two
forms detailed above in the correct order further corrob-
orating the correct identifications.
Conclusions
In this study, we extend the current information con-
cerning HMGA1a PTMs from human cells using vari-
ous methods including Top, and Middle Down, as well
as Bottom Up MS approaches. Through Bottom Up and
Middle Down MS proteomics, we find HMGA1a to be
highly modified at numerous sites with many different
types of PTMs (some novel), and with the exception of
the C-terminal phosphorylation, the majority of these
modifications are present at low abundance levels
(5%). Middle Down MS analysis allowed us to deter-
mine that some HMGA1a modifications can occur si-
multaneously, suggesting the potential of an HMGA1a
combinatorial PTM code analogous to the Histone Code;
however, this code was found to be much less complex or
much lower in abundance than expected. Results obtained
through a Top Down MS analysis were also consistent
with those results obtained through the other MS ap-
proaches, indicating that combinatorial modifications of
HMGA1a are not extensive in asynchronously grown
HeLa cells, but rather dominated by a few combinations
of the most abundant modifications (very limited spe-
cific codes). These data represent the first Top Down
MS analysis of HMGA1a, and provide a unique look at
HMGA1a modifications. Overall, we found that the
combined use of the different MS techniques is highly
complementary and allowed for a thorough character-
ization of HMGA1a modifications that could not be
accomplished by any one method alone. It will be
interesting to further probe both the single and combi-
natorial modifications of HMGA1a using this multifac-
eted MS approach during more specific biological con-
ditions such as during cancer progression or other
disease states.
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